Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 4,225 matching trials from the local directory fallback.

Filters: Intervention: PLACEBO Clear all

Conditions: Hypertension
Interventions: KMgCit, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autism Spectrum Disorder
Interventions: Functional Neurogenesis Stimulation Therapy, placebo control group; Device · Other
Lead sponsor: Neurocytonix, Inc.; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: ACL Injury, ACL Reconstruction, Scar Formation
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Control cream, Placebo cream- "prevention" suggestion, Placebo cream- "promotion" suggestion; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Pain, Placebo Effect, Rejection
Interventions: Control Cream with Naloxone, Control Cream with Saline, Placebo Cream with Naloxone, Placebo Cream with Saline; Drug
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: Placebo, glibenclamide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: BDNF, Cognition
Interventions: Placebo, d-beta-hydroxybutrate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postoperative Pain
Interventions: Acetaminophen Oral Tablet, Acetaminophen infusion, Placebo infusion, placebo oral tablet; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Menopausal Hot Flashes, Menopausal Women
Interventions: Placebo, ashwagandha root, ashwagandha root and leaf; Other · Dietary Supplement
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Dermatillomania, Trichotillomania (Hair-Pulling Disorder)
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Community Acquired Pneumonia (CAP), Sepsis
Interventions: OPT101, Placebo; Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions: Indomethacin, Placebo; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more

Conditions: Menopause
Interventions: Placebo, multi-vitamin, multi-nutrient; Dietary Supplement
Lead sponsor: Biologica Inc; Industry
Eligibility: 43 Years to 55 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation
Interventions: Intravenous caffeine, Masked Placebo; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 21 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Loma Linda, California • Overland Park, Kansas • Independence, Missouri + 2 more

Conditions: Coronary Artery Disease (CAD)
Interventions: A195/placebo, XC001; Drug
Lead sponsor: XyloCor Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HSV
Interventions: Benzoyl Peroxide 10% Bar, Placebo; Drug · Other
Lead sponsor: Greg Bew; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evans, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: ORMD-0801 16 mg, ORMD-0801 8 mg, Placebo capsule; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Dietary Supplement with actives, Placebo; Dietary Supplement
Lead sponsor: Olly, PBC; Industry
Eligibility: 5 Years to 14 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Healthy
Interventions: Maltodextrin (Placebo), Rice Bran, Soluble Arabinoxylan; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Healthy
Interventions: Dietary Supplement with actives, Placebo; Dietary Supplement
Lead sponsor: Olly, PBC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Healthy
Interventions: Dietary Supplement with actives, Placebo; Dietary Supplement
Lead sponsor: Olly, PBC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Inflammatory Bowel Diseases
Interventions: LpD3.5 supplementation., Placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: THC
Interventions: Placebo, THC; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Myocardial Infarction
Interventions: Dapansutrile, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 25 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans

Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

Individual Differences in Placebo Analgesic Effects

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

Oral Versus Intravenous Acetaminophen in Lumbar Spine Surgery

The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial

Aripiprazole in Body Focused Repetitive Behaviors

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

A Study to Investigate the Effect of a Multivitamin, Multi-nutrient Supplement on Mental and Emotional Wellbeing

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

A Clinical Study on the Effects of a Dietary Supplement on Stress, Anxiety, Mood and Sleep in a Pediatric Population

Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults

A Randomized, Placebo Controlled Clinical Study to Assess the Effect of a Blend of Digestive Enzymes and Extracts on Bloating in Adults.

A Randomized Double Blind, Placebo Controlled Clinical Study Evaluating the Efficacy and Safety of Magnesium Supplementation on Relaxation in Adults

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI